Jean-Pierre Bizzari, M.D. joined ADC Therapeutics as a Non-Executive Director of our board of directors in June 2022.
He is a member of the scientific advisory board of France’s National Cancer Institute and a board member of the European Organisation of Research and Treatment of Cancer. From 2008 to 2015, Dr. Bizzari served as Executive Vice President, Group Head of Clinical Development Oncology at Celgene Corporation. Prior to that, he held various senior clinical development positions at Sanofi S.A., Aventis and Rhône-Poulenc. In addition to our board of directors, Dr. Bizzari also serves as a member of the boards of directors of Halozyme Therapeutics, Inc., Oxford BioTherapeutics Limited, and Nordic Nanovector ASA, and previously served on the boards of directors of Transgene S.A., Onxeo SA and Compugen Limited. Dr. Bizzari holds an M.D. from Nice Medical School.